Stage 0 Pancreatic Cancer AJCC v8 Recruiting Phase 2 Trials for Camptothecin (DB04690)

IndicationStatusPhase
DBCOND0121165 (Stage 0 Pancreatic Cancer AJCC v8)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT04539808
NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic CancerTreatment